Free Trial

Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis

+0.10 (+0.23%)
(As of 10:45 AM ET)
Today's Range
50-Day Range
52-Week Range
61,857 shs
Average Volume
1.53 million shs
Market Capitalization
$5.18 billion
P/E Ratio
Dividend Yield
Price Target

Apellis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
80.1% Upside
$76.67 Price Target
Short Interest
10.21% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.08mentions of Apellis Pharmaceuticals in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$26.02 M Sold Last Quarter
Proj. Earnings Growth
From ($1.12) to $1.02 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.60 out of 5 stars

Medical Sector

80th out of 921 stocks

Pharmaceutical Preparations Industry

26th out of 421 stocks

APLS stock logo

About Apellis Pharmaceuticals Stock (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS Stock Price History

APLS Stock News Headlines

See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$396.59 million
Book Value
$1.64 per share


Free Float
Market Cap
$5.17 billion

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

APLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 3 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings
or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price target for 2024?

15 Wall Street analysts have issued 1 year price targets for Apellis Pharmaceuticals' shares. Their APLS share price targets range from $52.00 to $106.00. On average, they anticipate the company's share price to reach $76.67 in the next year. This suggests a possible upside of 80.1% from the stock's current price.
View analysts price targets for APLS
or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2024?

Apellis Pharmaceuticals' stock was trading at $59.86 at the beginning of the year. Since then, APLS shares have decreased by 28.9% and is now trading at $42.56.
View the best growth stocks for 2024 here

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024.
View our APLS earnings forecast

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). The company earned $172.33 million during the quarter, compared to the consensus estimate of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative trailing twelve-month return on equity of 160.77%. The business's quarterly revenue was up 284.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.56) earnings per share.

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

Apellis Pharmaceuticals (APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.84%), Jennison Associates LLC (2.67%), Price T Rowe Associates Inc. MD (2.03%), Assenagon Asset Management S.A. (1.68%), Artal Group S.A. (1.08%) and Iron Triangle Partners LP (0.45%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Caroline Baumal, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Apellis Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.
Read More
This page (NASDAQ:APLS) was last updated on 5/22/2024 by Staff

From Our Partners